At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 394 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Psoriatic Arthritis. Completed, enrolled 394 participants across 106 sites in 12 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesBulgaria, Czechia, Estonia, Mexico, Poland, Russia, Slovakia, South Africa, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedOct 2015
Primary CompletionOct 2018
TodayJul 2026
First PostedOct 23, 2015
Enrollment StartSep 14, 2015
Primary CompletionOct 30, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.7 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC